According to recent reports in the diabetes news, new clinical studies for a type 2 diabetes drug have started in the Netherlands. Initiated by Piramal Life Sciences Ltd, the oral drug will be tested on 72 volunteers.
Piramal submitted the clinical trial application (CTA) to the Netherlands regulatory board, the equivalent of the American Food and Drug Administration. Two panels approved the phase one clinical trials of the diabetic drug, the CCMO (Central Commission on Medical Research) and the BEBO (Independent Ethics Committee of the Foundation Evaluation of Ethics in Biomedical Research.)
Apparently, the results of the trials will be unveiled at the American Diabetes Association congress, which will be held in San Francisco in June. Piramal could create a novel treatment for type 2 diabetics .

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…